We envision a future where cancer is a curable disease. To achieve this, we aim to transform cancer care one blood sample at a time.
Get to know the people behind our solutions and services. Meet the team and the board – these are the talented people driving Simsen Diagnostics towards a brighter future.
SIMSEN DIAGNOSTICS
Team Members
CEO
Pontus Rehn
Pontus Rehn has over 20 years of experience in commercial leadership roles in the medical device and IVD industries, including global and regional positions like VP Market Development, Chief Commercial Officer, and Director of Commercial Strategy. SCHEDULE a call with Pontus below!
CTO
Stefan Filges
Stefan Filges, an accomplished bioinformatician with a Ph.D. in ultrasensitive sequencing, became part of Simsen Diagnostics in 2022. He played a crucial role as a co-author in the original publication of SiMSen-Seq, which was published in Nature Protocols.
QA/RA Manager
Jonna Eriksson
Jonna Eriksson holds a Ph.D. in genomics, bioinformatics, botany and evolution and has extensive experience from quality management and regulatory policies. Previous roles include Ass. Prof. at University of Skövde and Sr. R&D researcher at TATAA Biocenter.
Research Engineer
Niki Rostamzadeh
Niki Rostamzadeh leverages his prior experience with founder Anders Ståhlberg’s team, bringing a deep understanding of our technology to his current role. As our Research Engineer, he is responsible for managing R&D experiments and overseeing the handling of customer samples.
Schedule a Zoom meeting
BOARD OF DIRECTORS
Board Directors
Chairman of the Board
Anders Waas
Anders Waas is a business developer and investment manager at GU Venture with experience establishing start-ups in the life science sector. Anders has over 30 years of experience in the pharmaceutical and biotechnology industry as an advisor and CEO for multiple companies. He previously worked at the multinational pharmaceutical company AstraZeneca as a business developer and marketing director for over 13 years.
Board Director
Artur Aira
Artur is the CEO of Active Health. He is an experienced leader with more than 25 years of experience from pharma, diagnostics and biotechnology companies. Previous positions include CEO of Abigo Medical and SVP and BA manager of BICO. In addition, Artur has served on more than 30 company boards.
Board Director
Tony Godfrey
Tony Godfrey is professor at the Department of Surgery and Computational Biomedicine at Boston University School of Medicine. Tony co-invented SiMSen-Seq and developed further improvements of the technique. In addition, Tony has been an associate professor at several well-known universities in the US, such as the University of Rochester, The Mount Sinai Hospital, and the University of Pittsburgh.
Board Director
Dominique Gouty
Dominique is a Partner at Care Equity with over 20 years of experience in healthcare industry. Previous roles include CSO at BioAgilytix, Global Business Line Leader at Intertek and roles at Centocor, Amylin and Eli Lilly. She holds multiple patents and has published numerous peer-reviewed papers. She earned her PhD in Endocrinology from the University Timone Aix-Marseille II, School of Medicine, in France
Board Director
Christina Hall
Christina has been the CEO of Fujirebio Diagnostics AB for more than 14 years and has held management roles with similar diagnostics companies. Earlier, she has served as assistant professor of histology with the University of Gothenburg.
Board Director
Hanna Mann
Hanna is a seasoned professional with over 15 years of experience in the life science industry. With a background in molecular biology, she has successfully navigated various roles including commissioned research, sales management, sales enablement, and business development. Hanna’s primary focus is on driving the application of biomarkers in clinical settings, aiming to enhance healthcare outcomes.
Board Director
Mikael Kubista
Mikael Kubista is co-founder and former CEO of TATAA Biocenter and an expert in molecular technologies, and co-author of the MIQE guidelines. Mikael has business development skills within Bioinformatics, Real-Time Polymerase Chain Reaction (qPCR), Protein Chemistry Medical devices and RNA Isolation. In addition, Mikael has proven track record of developing biotech companies, including Life Genomics and Gendoktorn.
SIMSEN DIAGNOSTICS
Company history
2017
SiMSen-Seq published
The SimSen-Seq method published in Nature Protocols
2020
Simsen is founded
The inventors, Prof. Anders Ståhlberg and Prof. Tony Godfrey, decide to incorporate the company that will commercialise their invention - SiMSen-Seq. They founded the company together with Prof. Mikael Kubista and GU Ventures.
2021
Business begins
A 50 mSEK Vinnova grant was awarded and the company's first CEO and yet only employee was hired. Additional patent applications were submitted. Lab established at Sahlgrenska Science Park.
2022
Customers!
First customers sign on. A mix of research hospitals, and international diagnostics companies as well as pharmaceutical companies.
2023
Company Milestone
The office and lab moves to AstraZeneca's BioVentureHub in Mölndal on the outskirts of Gothenburg, Sweden.
2024
Growth
More customers sign on, including the first private cancer clinic. A new CEO is hired. A comprehensive QMS and GDPR framework is developed. A clear growth plan, including international expansion, is being commenced!
